Barely Significant
← all excerpts

Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

PLoS One · 2024 · PMC11265720 · PMID 39042627

Europe PMCDOI
1
hedged sentence
0.1000
closest p · 2.0× alpha
0.1000
boldest claim

The sentences

did not reach statistical significancep = 0.10so close (0.05 < p ≤ 0.1)
The difference between trials for SF-36 PF ≥ 90 did not reach statistical significance, i.e. 17.6% for CycloME versus 8.0% for RituxME (p = 0.10).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.